William Lewis Sells 129,805 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 129,805 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, June 3rd, William Lewis sold 5,472 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total transaction of $391,248.00.
• On Monday, June 2nd, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $71.31, for a total value of $487,047.30.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $67.72, for a total transaction of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The stock was sold at an average price of $67.65, for a total transaction of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The shares were sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80.

Insmed Stock Performance

Shares of INSM traded down $0.82 during midday trading on Thursday, reaching $99.46. The stock had a trading volume of 2,268,196 shares, compared to its average volume of 2,168,707. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The firm has a 50 day simple moving average of $73.43 and a 200-day simple moving average of $74.14. The firm has a market cap of $18.87 billion, a PE ratio of -16.72 and a beta of 0.80. Insmed, Inc. has a one year low of $60.40 and a one year high of $102.00.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the company earned ($1.06) earnings per share. The firm's revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently bought and sold shares of INSM. Vanguard Group Inc. boosted its stake in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after buying an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after purchasing an additional 219,131 shares during the last quarter. Capital International Investors grew its holdings in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Morgan Stanley raised their target price on Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a research note on Wednesday, June 11th. Bank of America boosted their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. HC Wainwright increased their target price on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Wells Fargo & Company lifted their price target on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 11th. Finally, Royal Bank Of Canada increased their price objective on Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $104.81.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.